Article
Chemistry, Medicinal
E. Scott Priestley, Jacques Banville, Daniel Deon, Laurence Dube, Marc Gagnon, Julia Guy, Philippe Lapointe, Jean-Francois Lavallee, Alain Martel, Serge Plamondon, Roger Remillard, Edward Ruediger, Francois Tremblay, Shana L. Posy, Victor R. Guarino, Jeremy M. Richter, Jianqing Li, Anuradha Gupta, Muthalagu Vetrichelvan, T. J. Balapragalathan, Arvind Mathur, Ji Hua, Mario Callejo, Jocelyne Guay, Chi Shing Sum, Mary Ellen Cvijic, Carol Watson, Pancras Wong, Jing Yang, Michel Bouvier, David A. Gordon, Ruth R. Wexler, Anne Marinier
Summary: Protease-activated receptor 4 (PAR4) plays a key role in blood coagulation and its importance in pathological thrombosis has been increasingly recognized. The optimized PAR4 antagonists, BMS-986120 and BMS-986141, demonstrated excellent antithrombotic efficacy and minimal bleeding time prolongation in monkey models, offering a potential opportunity to improve the standard of care in the treatment of arterial thrombosis.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Oncology
Ana Luisa Palacios-Acedo, Soraya Mezouar, Diane Mege, Lydie Crescence, Christophe Dubois, Laurence Panicot-Dubois
Summary: Platelet function can be altered by cancer cells in support of tumor growth, increasing the risk of thrombotic events in cancer patients. Research on P2RY12 drugs suggests that clopidogrel is more effective than aspirin in inhibiting cancer-associated thrombosis and tumor metastasis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Peng-Xin Ge, Ting Tai, Li -Ping Jiang, Jin-Zi Ji, Qiong-Yu Mi, Ting Zhu, Yi-Fei Li, Hong-Guang Xie
Summary: Choline and TMAO impair the metabolic activation of and platelet response to clopidogrel through the activation of the NOX-dependent ROS/Nrf2/CES1 pathway, suggesting novel strategies for overcoming clopidogrel resistance from bench to bedside.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Cardiac & Cardiovascular Systems
Erin A. Bohula, David D. Berg, Mathew S. Lopes, Jean M. Connors, Ijlal Babar, Christopher F. Barnett, Sunit-Preet Chaudhry, Amit Chopra, Wilson Ginete, Michael H. Ieong, Jason N. Katz, Edy Y. Kim, Julia F. Kuder, Emilio Mazza, Dalton McLean, Jarrod M. Mosier, Ari Moskowitz, Sabina A. Murphy, Michelle L. O'Donoghue, Jeong-Gun Park, Rajnish Prasad, Christian T. Ruff, Mohamad N. Shahrour, Shashank S. Sinha, Stephen D. Wiviott, Sean Van Diepen, Mark Zainea, Vivian Baird-Zars, Marc S. Sabatine, David A. Morrow
Summary: The study evaluated the efficacy and safety of prophylactic full-dose anticoagulation and antiplatelet therapy in critically ill COVID-19 patients. The results showed that full-dose anticoagulation can reduce the risk of thrombotic complications, but increases the risk of bleeding.
Article
Veterinary Sciences
Tomohiko Yoshida, Akiko Uemura, Ryou Tanaka, Ahmed Farag, Ahmed S. Mandour, Lina Hamabe, Kotaro Matsumoto
Summary: This article reports three cases of right atrial thrombosis in dogs, which were believed to be secondary to systemic diseases. Two cases were associated with hyperadrenocorticism and one case with pancreatitis and acute renal injury. The thrombi, located in the right atrium, were differentiated from cardiac neoplasia. The irregular structures with interspersed hypoechoic regions were confirmed as thrombi based on the response to therapy. The combination of clopidogrel and rivaroxaban was prescribed in all cases, leading to gradual disappearance of the thrombi. Complete resolution of right atrial thrombosis was achieved with this combination therapy, which was found to be safe and well tolerated. Thrombosis can be diagnosed through diligent observation of echocardiographic findings and clinical course.
VETERINARY MEDICINE AND SCIENCE
(2023)
Article
Peripheral Vascular Disease
Adam M. Berenson, Thomas N. Hawken, Daniel G. Fort, Samuel R. Money, Stephen R. Ramee, Waldemar Charles Sternbergh, Hernan A. Bazan
Summary: This study investigated the prevalence of clopidogrel resistance in patients undergoing coronary or endovascular interventions. The results showed that clopidogrel resistance or heightened platelet reactivity (HPR) was present in nearly half of patients with cardiovascular disease undergoing interventions. Evaluating patients for HPR is both inexpensive and rapid, and HPR appears to be more common in the cardiovascular patient population than previously appreciated. Future randomized studies are needed to determine the clinical impact of HPR on revascularization outcomes.
Article
Cell Biology
Xiangqi Wu, Wei You, Zhiming Wu, Qiang Wu, Jun Jiang, Hua Yan, Fei Ye, Shaoliang Chen
Summary: The study demonstrates that in patients undergoing second-generation DES implantation, the use of aspirin plus ticagrelor is associated with a significant reduction in subclinical stent thrombosis.
Review
Pharmacology & Pharmacy
Yingqi Zhang, Fengtao Jiang, Yunfeng Chen, Lining Arnold Ju
Summary: Platelet function tests play a crucial role in evaluating hemostasis and thrombosis. However, existing tests are often expensive, time-consuming, and lack accuracy. Microfluidic technologies have recently emerged as a promising alternative, offering high-throughput and cost-effective evaluation of platelet function in a physiologically relevant environment. These technologies have the potential to revolutionize patient monitoring and therapeutic evaluation.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Antonin Trimaille, Kensuke Matsushita, Benjamin Marchandot, Adrien Carmona, Sebastien Hess, Marion Kibler, Joe Heger, Antje Reydel, Laurent Sattler, Lelia Grunebaum, Laurence Jesel, Patrick Ohlmann, Olivier Morel
Summary: This study showed that baseline mean platelet volume (MPV) is an independent predictor of major/life-threatening bleeding complications one year after transcatheter aortic valve replacement (TAVR). Low MPV patients had higher risk of bleeding events, and factors such as preprocedural hemoglobin, L-MPV, and closure time adenosine diphosphate post-TAVR were identified as predictors of major bleeding complications.
Article
Biotechnology & Applied Microbiology
Zainab Omer Ali, Loulia Bader, Shaaban Mohammed, Salaheddin Arafa, Abdulrahman Arabi, Larisa Cavallari, Taimour Langaee, Fatima Mraiche, Nasser Rizk, Ahmed Awaisu, Mohamed H. Shahin, Hazem Elewa
Summary: The study demonstrated a significant association between the CYP2C19*17 allele and increased risk of bleeding, while CYP2C19*2 or *3 were associated with MACE outcomes.
PHARMACOGENETICS AND GENOMICS
(2022)
Review
Biochemistry & Molecular Biology
Dawn S. Kuszynski, D. Adam Lauver
Summary: Clopidogrel is a commonly used anti-thrombotic drug that acts by inhibiting the receptor on platelets. In addition to its effects on platelets, it may also have non-hemostatic effects on other tissues, possibly mediated by its metabolites.
PURINERGIC SIGNALLING
(2022)
Article
Cardiac & Cardiovascular Systems
Florian Fischer, Samriddhi Buxy, David J. Kurz, Franz R. Eberli, Oliver Senn, Rainer Zbinden, Ulrike Held, Matthias R. Meyer
Summary: In this study, eptifibatide administered as a sole bolus treatment in selected STEMI patients undergoing primary PCI was found to be non-inferior in terms of infarct size compared to conventional bolus and infusion treatment, while also resulting in fewer bleeding complications.
AMERICAN JOURNAL OF CARDIOLOGY
(2021)
Article
Veterinary Sciences
Matthew R. Kornya, Anthony C. G. Abrams-Ogg, Shauna L. Blois, R. Darren Wood
Summary: This study validated the shipping of blood samples for PFA-200 analysis in cats to determine the effect of clopidogrel. The results showed that shipping blood samples for PFA analysis is feasible and provides similar performance as point-of-care analyses.
VETERINARY CLINICAL PATHOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Ko Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, Takenori Domei, Masanobu Ohya, Manabu Ogita, Kensuke Takagi, Hirohiko Suzuki, Akira Nikaido, Mitsuru Ishii, Shinya Fujii, Masahiro Natsuaki, Satoshi Yasuda, Takeo Kaneko, Takashi Tamura, Toshihiro Tamura, Mitsuru Abe, Kazuya Kawai, Koichi Nakao, Kenji Ando, Kengo Tanabe, Yuji Ikari, Keiichi Igarashi Hanaoka, Yoshihiro Morino, Ken Kozuma, Kazushige Kadota, Yutaka Furukawa, Yoshihisa Nakagawa, Takeshi Kimura
Summary: In both complex and noncomplex PCI patients, clopidogrel monotherapy after 1-month DAPT showed comparable effects to 12-month DAPT on cardiovascular outcomes without significant interactions. Additionally, the 1-month DAPT group had significantly lower bleeding risk compared to the 12-month DAPT group regardless of PCI complexity.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS
(2021)
Article
Cardiac & Cardiovascular Systems
Benjamin E. Peterson, Robert A. Harrington, Gregg W. Stone, Ph Gabriel Steg, C. Michael Gibson, Christian W. Hamm, Matthew J. Price, Renato D. Lopes, Sergio Leonardi, Jayne Prats, Efthymios N. Deliargyris, Kenneth W. Mahaffey, Harvey D. White, Deepak L. Bhatt
Summary: This study analyzed randomized trial data and found that cangrelor is an effective and safe antiplatelet agent in patients undergoing percutaneous coronary intervention, regardless of obesity. There was no difference in short-term efficacy between obese and nonobese patients.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS
(2022)